Berlin, Germany-based ProBioGen has entered into a cell line development program with Millennium Pharmaceuticals of the USA. Under the customized program, ProBioGen will use its Position Mediated Expression Enhancement strategy, which has proved successful in the development of high-yielding cell lines, to develop cell lines for the US company's antibodies and manufacture preclinical trial materials.
Through the use of Boost Elements and a specific design, ProBioGen claims it is in a position to shorten development time and meet customer expectations even under aggressive timelines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze